Splash Beverage Group, INC

Endovia Health Sciences has amended its equity line of credit agreement, increasing the total commitment from $35 million to $135 million.

Endovia Health Sciences has amended its equity line of credit facility with C/M Capital Master Fund, LP, increasing the beneficial ownership limitation.

Endovia Health Sciences disclosed the sale of 526,582 shares of common stock for gross proceeds of $81,830.84 under an existing agreement.

Endovia Health Sciences announced its investigational drug CannEpil has been determined by the FDA to qualify as a minor use for canine bone cancer pain, paving the way for conditional approval.

Endovia Health Sciences, Inc. has issued a secured convertible promissory note to C/M Capital Master Fund, LP, for $510,000, with provisions for conversion into common stock and specific repayment terms.

Endovia Health Sciences announced the closure of an initial $500,000 financing tranche from C/M Capital to advance its CannEpil development program, coinciding with increased federal support for botanical drug pathways.

Splash Beverage Group reports a significant strategic pivot towards the cannabinoid market with a proposed Medterra acquisition, alongside a substantial decrease in beverage revenue and ongoing liquidity concerns.

Splash Beverage Group reported a significant net loss for Q3 2025, with no revenue generated since March, while pursuing strategic shifts into water extraction and tequila distribution, and addressing liquidity challenges.

Splash Beverage Group reported increased net losses and significant balance sheet restructuring, including debt-to-equity conversions and a $20M water rights acquisition, while regaining NYSE American listing compliance.

Splash Beverage Group, Inc. reported a significant decline in Q1 2025 revenues, negative gross profit, and zero cash, prompting a going concern warning and strategic debt-to-equity conversions to address severe financial distress and NYSE listing non-compliance.

Splash Beverage Group's Q3 2024 results show a significant decrease in revenue compared to the same period last year, alongside an increase in debt and ongoing concerns about the company's ability to continue as a going concern.

Splash Beverage Group's Q2 2024 results show a significant decrease in revenue and an increase in net loss compared to the same period last year, alongside concerns about the company's ability to continue as a going concern.

Splash Beverage Group files an amendment to its 2025 Annual Report to include required Part III disclosures regarding governance and executive compensation.

Splash Beverage Group's 2025 10-K reveals significant revenue decline and ongoing going concern issues, while pursuing a potential acquisition of Medterra CBD.

Splash Beverage Group, Inc. reported a significant revenue drop and substantial net losses for fiscal year 2024, leading to a 'going concern' audit opinion and a formal delisting notice from NYSE American.

Splash Beverage Group's 2023 annual report reveals a net loss of $21 million and ongoing concerns about the company's ability to continue as a going concern.

Michael Bondurant, Chief Operating Officer of SPLASH BEVERAGE GROUP, INC., was granted 800,000 stock options with an exercise price of $0.25, vesting immediately.

Director Thomas Butler Fore was granted 500,000 non-qualified stock options in Splash Beverage Group, Inc.

Director Frederick William Caple was granted 500,000 non-qualified stock options in Splash Beverage Group, Inc.

Director Francis Knuettel II was granted 500,000 fully vested stock options in Splash Beverage Group, Inc.

Interim CEO Brady James Cobb was granted 925,000 stock options in Splash Beverage Group, Inc. as part of the 2025 Equity Incentive Plan.

Interim CFO Martin P. Scott was granted 700,000 fully vested stock options in Splash Beverage Group, Inc.

Endovia Health Sciences is holding a special meeting on December 7, 2026, to vote on proposals including stock issuances, an authorized share increase, and a reverse stock split, crucial for its continued listing and financing.

Endovia Health Sciences, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, executive compensation, and amendments to its equity incentive plan.

Splash Beverage Group, Inc. has adjourned its 2025 Annual Meeting of Stockholders to November 14, 2025, to allow for further proxy solicitation and voting on Proposal 6.

Splash Beverage Group, Inc. is seeking shareholder approval for critical proposals including significant common stock issuances and an equity incentive plan to address its severe capital needs and maintain NYSE American listing.

Splash Beverage Group, Inc. has filed an amendment to its proxy statement, confirming it has regained compliance with NYSE American listing standards after addressing prior deficiencies and late filings.

Splash Beverage Group, Inc. will hold a special meeting on August 29, 2025, to vote on increasing its authorized common stock from 7.5 million to 400 million shares, a move the company states is crucial for future financing and operational flexibility.

Endovia Health Sciences, Inc. has filed an S-1 registration statement to allow for the resale of up to 1,013,041 shares of its common stock by C/M Capital Master Fund, LP.

Splash Beverage Group, Inc. (SBEV) has filed an S-1/A amendment to register the resale of up to 5,000,000 shares of common stock by C/M Capital Master Fund, LP, detailing a strategic shift towards the cannabinoid and wellness sectors.

Splash Beverage Group, Inc. has filed a Form S-1 with the SEC to register up to 5,000,000 shares of its common stock for resale by C/M Capital Master Fund, LP.

Splash Beverage Group files a registration statement for the potential resale of up to 10,000,000 shares of common stock issued under an existing equity line of credit.

Splash Beverage Group, Inc. filed an S-1 registration statement for the resale of up to 7.76 million common shares by selling stockholders, highlighting severe liquidity issues, recurring losses, and a critical need for capital to resume operations and pursue new ventures.

Splash Beverage Group, Inc. (SBEV) has not generated revenue since March 2025, raising substantial doubt about its ability to continue as a going concern, despite securing a $35 million equity line of credit.

Splash Beverage Group director Thomas Fore reports beneficial ownership of 23.7% of the company's common stock through warrants, signaling an intent to exercise control.

Robert Nistico, CEO and Chairman of Splash Beverage Group, Inc., reported beneficial ownership of 7.1% of the company's common stock, primarily through warrants and options.

Splash Beverage Group's CFO, William T. Devereux, reported beneficial ownership of 29.4% of the company's common stock, primarily through warrants and options received as part of his employment.

Frederick William Caple, a director of Splash Beverage Group, Inc., has reported beneficial ownership of 24.1% of the company's common stock with the stated purpose of exercising control.

Splash Beverage Group director Justin W. Yorke has increased his beneficial ownership to 28.6% of common stock, signaling intent to exercise control.

William R. Meissner, President and Chief Marketing Officer of Splash Beverage Group, Inc., reported beneficial ownership of 23.8% of the company's common stock, primarily through warrants.

C/M Capital Master Fund, LP, along with related entities and individuals, has reported beneficial ownership of 7.2% of Endovia Health Sciences, Inc. common stock.

Aida Aragon has reported beneficial ownership of 5.8% of Splash Beverage Group, Inc.'s common stock, primarily through warrants.

Magdalene Tong has reported beneficial ownership of 7.7% of Splash Beverage Group, Inc.'s common stock, primarily through warrants.